Abstracts Archive - Page 135 of 2425 - ACR Meeting Abstracts

Abstract Number: 1951 • ACR Convergence 2024
Patient-Reported Barriers to Care Across Pediatric Rheumatology Patients at a Tertiary Academic Medical Center
Bethany Walker¹, Carolyn Smith², John Bridges³, Linda McAllister¹, Ashley McCamy⁴, Annelle Reed⁵, Erica Reynolds⁴, Isabella Robles², Livie Timmerman⁶, Tana Webb², Melissa Mannion⁷ and Emily Smitherman⁷, ¹Children's of Alabama, Trussville, AL, ²Children's of Alabama, Birmingham, AL, ³University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ⁴Children's of Alabama, Birmingham, ⁵Children's of Alabama, Tuscaloosa, AL, ⁶University of Alabama at Birmingham, Gardendale, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Pediatric rheumatic diseases require frequent medical interactions, including follow-up visits with various providers, lab testing, imaging procedures, and infusion treatments. The impact of these…
Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
JM JANSZ¹, EA Troy², WL Galanter³, Elaine Adams⁴, Nadera Sweiss⁵ and HJ CHANG⁶, ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Woodridge, IL, ³University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ⁴Jesse Brown VA Medical Center, La Grange, IL, ⁵University of IL, Chicago, IL, ⁶RHEUMATOLOGIST, CHICAGO, IL
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Ronald Van Vollenhoven¹, Joseph Merola², Kathryn H. Dao³, Piotr Leszczynski⁴, Marilyn Pike⁵, Samantha Pomponi⁶, Coburn Hobar⁶, Matthew J. Colombo⁶, Ravi Koti⁶, Subhashis Banerjee⁶, Thomas Wegman⁷ and Eric Morand⁸, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ²UT Southwestern Medical Center, Newton, MA, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, ⁴Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, ⁵Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Beaver Falls, PA, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…
Abstract Number: 1919 • ACR Convergence 2024
Patient-reported Social Risk Factor Screening Among Rheumatology Outpatients
Alissa Chandler¹, Mohammed Hamid², Aurora Jiao³, Kelsey Hulcher⁴, Isha Sharma⁵, Patrice Odom⁴, Andrew Robinson⁶, Sara Kellahan², Maura Kepper⁷, Colleen Dostal⁸, Senada Fenelon⁹, Seth Eisen¹⁰, Daphne Lew¹¹ and Alfred Kim¹², ¹Washington University, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO, ³Washington University, Saint Louis, ⁴Washington University, Saint Louis, MO, ⁵Washington University in St. Louis School of Medicine, San Jose, CA, ⁶Washington University, Fenton, MO, ⁷Washington University, Brown School of Social Work, Saint Louis, ⁸Southern Illinois University Edwardsville, St. Louis, MO, ⁹Washington University St Louis, Ballwin, MO, ¹⁰Washington University School of Medicine, St Louis, MO, ¹¹Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO
Background/Purpose: The purpose of this study was to pilot test a patient-reported social risk factor (SRF) screening tool among rheumatology outpatients and to examine the…
Abstract Number: 1774 • ACR Convergence 2024
Metabolomics and Lipidomics in Juvenile Localized Scleroderma
Yuan Zhang¹, Angela Aquilani², Rebecca Nicolai³, Fabrizio De Benedetti⁴, Emiliano Marasco² and Cristina Maglio¹, ¹University of Gothenburg, Gothenburg, Sweden, ²Bambino Gesù Children’s Hospital, Immunology and Rheumatology Unit, Roma, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Juvenile localised scleroderma (jLS) is a rare rheumatic disease in children characterized by inflammation and fibrosis in the skin [1, 2]. The cause and…
Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
S. Ahmed¹, Eva Hoekstra², Katie van der Wouden², Sum-Che Man², Kees Swenne², Madelon Vonk³, Anna-Maria Hoffmann-Vold⁴, Cosimo Bruni⁵, Udo Mulder⁶, Thomas Huizinga⁷, H.W. Vliegen² and Jeska de Vries-Bouwstra², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Oslo University Hospital, Oslo, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…
Abstract Number: 1916 • ACR Convergence 2024
Healthcare Disparities and Clinical Outcomes in Cardiac Sarcoidosis. a Retrospective Cohort Study
Yurilu Gonzalez Moret¹, Diego Lema², kevin Lo³ and Fabian Rodriguez Quinonez⁴, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Brigham and Women's Hospital, Boston, MA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Sarcoidosis is a condition affecting multiple organ systems, characterized by the presence of non-caseating granulomas. Cardiac sarcoidosis (CS) is a challenging diagnosis, with a…
Abstract Number: 1791 • ACR Convergence 2024
A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Matthew Muller¹, Elliot Luttrell-Williams¹, Haley Rosmann², Kelly Ruggles³, Jill Buyon⁴ and Jeffrey Berger¹, ¹NYU Langone, New York City, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, Brooklyn, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…
Abstract Number: 0017 • ACR Convergence 2024
Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction
Sang Jin Lee¹, Nan Young Lee², Eun Joo Lee³, Ji Ae Jang³, Gun Woo Kim³ and Eon Jeong Nam², ¹Kyungpook National University Hospital, Daegu, Republic of Korea, ²Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, ³Daegu Fatima Hospital, Daegu, Republic of Korea
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a prototypical autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, where complex interactions between innate and adaptive…
Abstract Number: 0058 • ACR Convergence 2024
Bradykinin Receptor B1 Blockade Suppresses Soluble CD13-Induced Differentiation of Osteoclasts from Monocytes
Sei Muraoka¹, Qi Wu², Mikel Gurrea-Rubio³, Camila Amarista², William Brodie², Megan Mattichak², Yuzo Ikari⁴, Caroline Foster², Phillip Campbell², David Fox⁵ and Pei-Suen Tsou², ¹University of Michigan, Toyko, Japan, ²University of Michigan, Ann Arbor, MI, ³University of Michigan - Ann Arbor, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Dexter, MI
Background/Purpose: CD13 is an ectopeptidase expressed on myeloid cells, endothelial cells, and rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). Soluble (s) CD13 is generated by matrix…
Abstract Number: 1819 • ACR Convergence 2024
Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis
Ye Jin Jeong¹, Gayathri Guru Murthy¹, Gaochan Wang¹, Tahia Rahman¹ and Benjamin Korman², ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
Abstract Number: 1566 • ACR Convergence 2024
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
Sumbal Wajid¹, Lee Shapiro², Virginia Steen³, Robyn Domsic⁴, Paul J. Feustel⁵ and Swati Mehta⁶, ¹Albany Medical Center, Albany, NY, ²Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, ³Georgetown University School of Medicine, Washington, DC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
Abstract Number: 1922 • ACR Convergence 2024
Insights into Rheumatology Practice in Uganda
Marwin Groener¹, Evelyn Hsieh², Lillian Tugume³ and Mark Kaddumukasa³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT, ³Makerere University Kampala, Kampala, Uganda
Background/Purpose: Data regarding the prevalence of rheumatic diseases in sub-Saharan Africa is scarce and only a small number of rheumatologists practice in this region. Uganda…
Abstract Number: 1806 • ACR Convergence 2024
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
Holme Vestin¹, Nina Oparina², Maija-Leena Eloranta¹, Martina Frodlund³, Iva Gunnarsson⁴, Christopher Sjowall⁵, Elisabet Svenungsson⁶, Lars Rönnblom¹, Ann-Christine Syvänen¹, Johanna Sandling¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Uppsala university, Uppsala, Sweden, ²UU, Uppsala, Sweden, ³Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Linköping University, Linköping, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by production of auto-antibodies, immune complex formation and an activated type I interferon system. Both genetic and environmental…
Abstract Number: 1024 • ACR Convergence 2024
Increased Social Vulnerability Index Predicts Lower Likelihood of Remission in Rheumatoid Arthritis Patients
Daniel Montes¹, Elena Myasoedova¹, Chanakya Kodishala¹, Roslin Jose George¹, Andrew C. Hanson², Vanessa Kronzer¹, John Davis¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Adverse social determinants of health (SDoH) are associated with poorer short- and long-term health outcomes. Prior studies have reported considerable prevalence of adverse SDoH…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].